logo-loader

ANGLE strengthens intellectual property claims for Parsortix device

Published: 02:30 08 Apr 2014 EDT

blood_cells350_53439bf223d4f

ANGLE (LON:AGL) has made recent patent submissions for its potentially breakthough Parsortix diagnostic system, which could protect the firm's value until at least 2033, it said.

Over the past months, the medtech specialist has established a third party of patents and has filed applications worldwide for these, it said.

The group's founder and chief executive Andrew Newland said: "Our intellectual property strategy is key to our business and this strengthening of our IP is an important commercial milestone."

He said the patents allow for the expansion of the Parsortix system for use in several areas in addition to the core cancer areas currently under development and protected by granted patents.

Parsortix can harvest circulating tumour cells found in the blood - allowing for the early detection of cancer.

The new patents cover new operational aspects of the technology, including the cell harvesting and cell measurement method.

It also covers the design of the cassette to provide an increase in separating capacity.

The first family of patents is protected by an issued US Patent, which expires in 2026 and has a second pending US patent which expires in 2022, subject to extension.

The second, which covers numerous improvements, including device geometry and flow, has a US patent pending which, if granted, would provide protection to 2029, subject to extension.

ANGLE PLC present at the Proactive One2One Investor Conference - January 11th

In a comprehensive presentation at the Proactive One2One Investor Conference, ANGLE PLC (AIM:AGL, OTCQX:ANPCY) CEO, Andrew Newland, and CFO, Ian Griffiths, detailed the company's innovative approach to cancer diagnosis and treatment. Newland emphasised ANGLE's breakthrough technology, the...

on 01/17/2024